Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Non-Current Deffered Revenue (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Non-Current Deffered Revenue data on record, last reported at $53.0 million in Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue fell 81.66% year-over-year to $53.0 million; the TTM value through Sep 2025 reached $53.0 million, down 81.66%, while the annual FY2023 figure was $307.0 million, 13.52% down from the prior year.
  • Non-Current Deffered Revenue reached $53.0 million in Q3 2025 per RCUS's latest filing, down from $60.0 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $462.0 million in Q4 2021 and bottomed at $53.0 million in Q3 2025.
  • Average Non-Current Deffered Revenue over 5 years is $272.9 million, with a median of $318.5 million recorded in 2023.
  • Peak YoY movement for Non-Current Deffered Revenue: skyrocketed 1003.67% in 2021, then plummeted 81.66% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $462.0 million in 2021, then decreased by 23.16% to $355.0 million in 2022, then decreased by 13.52% to $307.0 million in 2023, then dropped by 5.86% to $289.0 million in 2024, then tumbled by 81.66% to $53.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $53.0 million in Q3 2025, $60.0 million in Q2 2025, and $289.0 million in Q3 2024.